

Transcription factor Snail-1 induces osteosarcoma invasion and metastasis by inhibiting E-cadherin expression

HUIGUANG YANG, YUNQING ZHANG, ZHENGMING ZHOU, XUEFENG JIANG and AIDONG SHEN

Department of Orthopaedics, The Affiliated Jiangyin Hospital of Southeast University Medical College,
Jiangyin, Jiangsu 214400, P.R. China

Received June 24, 2013; Accepted March 4, 2014

DOI: 10.3892/ol.2014.2079

Abstract. Osteosarcoma (OS) is a type of primary malignant bone tumor with a high propensity for local recurrence and distant metastasis. A previous study showed Snail-1 is highly expressed in OS cells. The present study aimed to investigate the association between the transcription factor Snail and E-cadherin in OS. SaOS₂ OS cells were transfected either with a plasmid expressing short hairpin RNA (shRNA) specific for the Snail-1 gene (SaOS₂-shRNA) or a negative control plasmid (SaOS₂-Mock). The expression levels of E-cadherin and Snail-1 in the transfected and control cells were determined by quantitative polymerase chain reaction and western blot analysis. In addition, the study was extended to evaluate the migratory and invasive properties of the cells through a Transwell experiment. The results show that E-cadherin was expressed at a high level in the SaOS₂-shRNA cells, which were much less migratory and invasive than the control cells. Overexpression of Snail-1 in OS is associated with tumor progression, possibly through the suppression of E-cadherin expression and induction of the process of epithelial-mesenchymal transition, which contributes to the proceeding invasion and metastasis of OS cells.

Introduction

Osteosarcoma (OS) is the most common type of primary malignancy of bone. Despite intensive chemotherapy and adequate surgical resection, ~30-50% of patients succumb to OS, mainly due to distant metastasis to the lung (1,2). Snail-1 is a zinc-finger transcription factor expressed in migratory

processes during embryonic development that has been implicated in cancer (3,4). A previous study showed that Snail-1 is highly expressed in OS cells, and is associated with the migratory and invasive properties of OS cells (5).

Studies have shown that Snail-1 upregulation in epithelial cells induces the expression of E-cadherin. Snail-1 contributes to the maintenance of the adhesive and polarized phenotype of epithelial cells where it is mainly expressed (6). If E-cadherin expression is downregulated, the epithelial cells acquire a fibroblastoid morphotype accompanied by the acquisition of invasive and migratory properties (7-9). This event is critical for the invasion and metastasis of carcinoma cells (10,1). Therefore, the loss of E-cadherin expression may be considered as an indicator of poor clinical prognosis and it is important to identify the molecular mechanism that regulates the expression of E-cadherin. A study has identified that E-cadherin is regulated by transcriptional factors such as Snail-1 (12). In the present study, whether Snail-1 regulates E-cadherin expression in OS cells was investigated and the association between E-cadherin expression and the migratory and invasive properties of the cells was explored

Materials and methods

Cell line and culture. The human SaOS₂ OS cell line was purchased from the China Center for Type Culture Collection (Wuhan, China). The cells were cultured in McCoy's 5A medium (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS; Hangzhou Sijiqing Biological Engineering Materials Co. Ltd., Hangzhou, China) and antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) in humidified air with a 5% CO₂ atmosphere at 37°C (Thermo Direct Heat CO₂ incubator; Thermo Fisher Scientific, Waltham, MA, USA). The study was approved by the ethics committee of the Affiliated Jiangyin People's Hospital of Southeast University Medical College (Jiangyin, Jiangsu).

Transfection. The SaOS₂ cells were plated in 100-mm dishes and transfected at 50-80% confluence with an expression vector for short hairpin RNA (shRNA) targeting Snail-1 or with a control vector, using the liposome-mediated transfection method (5). To establish cells in which Snail-1 expression

Correspondence to: Professor Huiguang Yang, Department of Orthopaedics, The Affiliated Jiangyin Hospital of Southeast University Medical College, 163 Shoushan Road, Jiangyin, Jiangsu 214400, P.R. China
E-mail: yanghuiguang@126.com

Key words: Snail-1, E-cadherin, epithelial-mesenchymal transition, osteosarcoma

was stably suppressed and mock-transfected cells, the SaOS₂ cells were transfected with a plasmid (pcDNA3.1/shSnail-1 or pcDNA3.1/GAPDH, respectively; Introgen Therapeutics Inc., Austin, TX, USA) for two days. The cells were then trypsinized and plated at a low density. The stable clones were selected by maintaining the cells in medium containing the antibiotic G418 (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China).

Animal. BALB/c nude mice (between six and seven weeks old) were obtained from the Shanghai SLRC Laboratory Animal Co., Ltd. (license no. SCXK [hu] 2007-0005; Shanghai, China). The mice were bred and housed in a pathogen free, temperature-controlled and air-conditioned environment with a 10/14 h light/dark cycle. Two groups of these immunodeficient mice were subcutaneously injected with either mock- or Snail-1 shRNA-transfected cells [1×10^6 cells/200 μ l phosphate-buffered saline (PBS)]. Tumor growth was measured with a caliper two or three times every two days. Tumor volume was calculated using the following formula: Volume = $(L \times W^2)/2$, where L is the tumor length and W is the tumor width (both in millimeters) and $L > W$. After 17 days the mice were sacrificed in accordance with the guidelines for the welfare of animals in experimental neoplasia and the tissues were stored at -80°C .

Cell viability assay. The viability of the cells was determined by the Cell Counting kit-8 (CCK-8; Nanjing KeyGen Biotech. Co. Ltd., Nanjing, China) assay. The cells (1×10^4 /well) were plated in 96-well plates in 200 μ l medium per well. At different time points, the CCK-8 solution was added and the cells were cultured for 4 h. The absorbance at 570 nm was measured with a microplate reader (Sunrise; Tecan, Männedorf, Switzerland), using wells without cells as blanks and using untreated cells as the negative control. Cell death was calculated as a percentage of inhibition using the following formula: inhibition (%) = $(1 - \text{mean experimental absorbance}/\text{mean control absorbance}) \times 100$.

Apoptosis detection. Apoptosis detection of the cells was performed using a TRITC Staining Apoptosis Detection kit (Nanjing KeyGen Biotech. Co. Ltd.) and flow cytometry (BD Biosciences, San Jose, CA, USA). Briefly, the cells were trypsinized, washed with PBS, centrifuged and fixed for 20 min at $15\text{--}25^\circ\text{C}$ (fixation solution: 4% paraformaldehyde in PBS buffer, pH 7.4, freshly prepared). The cells were washed for 30 min with PBS, and then were incubated with blocking solution for 10 min at $15\text{--}25^\circ\text{C}$ (the blocking solution contained 3% H₂O₂ in methanol). Subsequently, the cells were incubated in permeabilization solution for 2 min on ice ($2\text{--}8^\circ\text{C}$; the permeabilization solution contained 0.1% Triton X-100 and 0.1% sodium citrate, freshly prepared). Terminal deoxynucleotidyl transferase (TdT) dUTP nick end labeling (TUNEL) reaction mixture (50 μ l; Nanjing KeyGen Biotech Co., Ltd.) was added to the samples and the samples were incubated for 60 min at 37°C in a wet and dark atmosphere (TUNEL reaction mixture contained 45 μ l equilibration buffer, 1 μ l TRITC-5-dUTP and 4 μ l TdT, freshly prepared), then resuspended in 500 μ l 4',6-diamidino-2-phenylindole (DAPI)/RNase buffer (Nanjing KeyGen Biotech Co., Ltd.) and incubated for 30 min at 37°C . The samples were assayed by fluorescence microscopy using an excitation wavelength

of 543 nm and emission wavelength of 571 nm (green) within 1 h.

Matrigel invasion assay. A modified Boyden chamber (Neuro Probe Inc., Gaithersburg, MD, USA) was used. The pore size of the polycarbonate filters was 8.0 μ m. The bottom chamber of the Transwell chamber was filled with 30 ml McCoy's 5A medium containing 10% FBS. The cells were then suspended at a density of 1×10^5 cells/ml in 500 μ l McCoy's 5A medium supplemented with 0.5% FBS, and 1,25(OH)₂-D₃ with a concentration of 10^{-6} M was added to the 8-mm porous BD BioCoat Matrigel chamber inserts (BD Biosciences, San Jose, CA, USA). Subsequently, the inserts were placed in the wells which were filled with 0.7 ml medium supplemented with 10% fetal calf serum as a chemoattractant. After two days of incubation, the upper side of the filter was scraped with a cotton tip to eliminate cells that had not migrated through it. The invasive ability of the cells was determined by counting the cells that had migrated to the lower side of the filter with a microscope. The experiments were performed in triplicate and ≥ 10 fields were counted in each experiment.

Western blot analysis. The proteins were extracted from the SaOS₂ cells in lysis buffer and then separated by SDS-PAGE and electrophoretically transferred onto polyvinylidene difluoride membranes. The membranes were probed with primary antibodies overnight at 4°C , and then incubated with the secondary antibodies. The images of the western blot products were collected and analyzed with Quantity One V4.31 software (Bio-Rad, Hercules, CA, USA). The primary Snail-1 and E-cadherin polyclonal antibodies were purchased from Abnova (Taiwan, China). Goat anti-mouse HRP-conjugated secondary antibody was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) and goat anti-rabbit HRP-conjugated secondary antibody was purchased from Amersham Pharmacia Biotech (Piscataway, NJ, USA).

Quantitative polymerase chain reaction (qPCR). Total RNA was isolated from the SaOS₂ cells using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. The reverse transcription reactions were conducted with a Transcriptor First Strand cDNA Synthesis kit (Roche, Indianapolis, IN, USA). The PCR primers were designed by Premier Primer software, version 5.0 (Premier Biosoft, Palo Alto, CA, USA). qPCR with SYBR Green PCR Master mix (Applied Biosystems, Foster City, CA, USA) was performed using an ABI Prism 7500 Sequence Detection system (Applied Biosystems). The fluorescent signals were collected during the extension phase, the Ct values of the sample were calculated and the transcript levels were analyzed by the $2^{-\Delta\Delta\text{Ct}}$ method.

Data analysis. Statistical comparisons were performed with the software package SPSS, version 13.0 (SPSS, Inc., Chicago, IL, USA) using Student's t-test for paired observations or one-way analysis of variance with Student-Newman-Keuls, least significant difference and Dunnett's methods. All data are presented as the mean \pm standard deviation (SD).




Figure 1. E-cadherin and Snail-1 expression levels following inhibition of Snail-1 in SaOS₂ cells analyzed by western blotting and qPCR. GAPDH was used as a loading control. The relative (A and B) protein and (C) mRNA expression levels of Snail-1 and E-cadherin. The results are presented as the mean \pm SD. The experiments were performed in triplicate.

$P < 0.05$ was considered to indicate a statistically significant difference. The mean values and SD were calculated for the experiments conducted in triplicate.

Results

Inhibition of Snail-1 increases the expression levels of E-cadherin in SaOS₂ cells. To determine the association between Snail-1 and E-cadherin, shRNA targeting Snail-1 was successfully transfected into SaOS₂ cells and the expression levels of Snail-1 and E-cadherin in the cells were detected by western blot analysis. To confirm the efficacy of Snail-1 shRNA, qPCR and western blot analysis were performed (data not shown). The expression levels of E-cadherin in the SaOS₂ cells transfected with the Snail-1-shRNA vector were significantly higher than those in the SaOS₂ cells with no treatment (control group) or infected with the negative control shRNA (shRNA-Mock) (Fig. 1). Therefore, inhibition of Snail-1 expression in SaOS₂ cells resulted in higher levels of E-cadherin protein expression.

Proliferation of SaOS₂ cells and Snail-1-shRNA-transfected SaOS₂ cells. CCK-8 assays were performed to investigate the proliferation of the SaOS₂ cells transfected with shRNA-Mock




Figure 2. Comparison of the levels of growth inhibition of SaOS₂ cells after different time periods. Growth inhibition was determined by the CCK-8 assay. (□)shRNA-Snail-1 group, (▲)shRNA-Mock group and (△)control group) * $P < 0.05$ vs. control group. CCK-8, cell counting kit-8.




Figure 3. Comparison of the apoptotic rate of SaOS₂ cells following transfection with shRNA-Snail-1 at different time periods. * $P < 0.05$, indicating that the rate of apoptosis was significantly higher than that of the control (con) and shRNA-mock groups.

and shRNA-Snail-1. The growth inhibition of all cells increased in a time-dependent manner (Fig. 2). The results suggest that the growth of the SaOS₂ cells was inhibited significantly when Snail-1 expression was inhibited ($P < 0.05$).

Apoptosis differs between normal and sh-Snail-1-transfected SaOS₂ cells. A quantitative analysis of the fluorescent signals of the cells was performed by fluorescence-activated cell sorting. As shown in Fig. 3, the percentage of TRITC-positive SaOS₂ cells was significantly increased from 12.3% in the control group to 20.3% in the SaOS₂ cells transfected with shRNA-Snail-1 after treatment for 48 h ($P < 0.05$). These data indicate that the rate of apoptosis of the SaOS₂ cells increased when Snail-1 expression was inhibited.

Change of the invasive ability of SaOS₂ cells following transfection with shRNA-Snail-1. A significant difference in the number of invading cells was observed between the SaOS₂ cells transfected with shRNA-mock and those transfected with shRNA-Snail-1 in the migration assay. Furthermore, the invasion rate of the SaOS₂ cells transfected with shRNA-Snail-1 was significantly lower than that of the control SaOS₂ cells ($P < 0.05$) in the Matrigel invasion assay (Fig. 4).

Tumor growth in vivo. Tumor growth was attenuated in the animals injected with cells transfected with shRNA-mock




Figure 4. Invasiveness of SaOS₂ cells. Cell invasion 48 h after treatment was evaluated in the Matrigel invasion assay. (A) Representative microscopic images of (a) untreated control cells, (b) cells transfected with shRNA-mock and (c) cells transfected with shRNA-Snail-1 after treatment (x200). (B) Comparison of the rate of cell invasion. Data are expressed as the percentage change (mean \pm SD) and represent three independent experiments. * $P < 0.05$ vs. control.




Figure 5. Growth of SaOS₂ cells xenografted into BALB/c nude mice. The SaOS₂ cells were implanted subcutaneously into the flanks of the mice. (A) Photograph of the SaOS₂ tumors from the mice at day 17 after implantation in the (a) shRNA-mock and (b) shRNA-Snail-1 groups. (B) The tumor volume following implantation. White squares indicate the shRNA-mock group and black squares indicate the shRNA-Snail-1 group. Data are presented as the mean \pm SEM ($n = 5$ in each group). (C) Levels of E-cadherin detected in the tumor tissues. * $P < 0.05$ vs. shRNA-mock group.

cells than in those injected with cells transfected with shRNA-Snail-1 (Fig. 5). The tumors generated by the cells transfected with shRNA-Snail-1 were less differentiated with much lower E-cadherin expression levels than those observed in shRNA-mock-transfected cells.

Discussion

OS is the most common type of primary malignant tumor of bone in children and young adolescents (13,14). With the use of chemotherapeutics in combination with aggressive surgery, the long-term survival rate of patients has improved (15). However, a number of patients have metastases at initial diagnosis, which is common to the lung (16). Therefore, to more effectively control this disease and improve the patient survival rate, it is important to elucidate the molecular mechanism of human sarcomagenesis and to develop novel treatment options for OS.

Epithelial-mesenchymal transition (EMT) has been widely studied for its role in early development and cancer metastasis. EMT results in the transformation of a differentiated epithelial cell to a mesenchymal cell with stem-like properties and is characterized by loss of cell-to-cell adhesion, specifically through the dismantling of adherens, tight and gap junctions, as well as loss of cell polarity and increased motility (17,18). In embryogenesis, EMT functions

by promoting the migration of mesenchymal cells during gastrulation and neural crest cell migration, then later during tissue remodeling and organogenesis, ultimately contributing to the development of differentiated tissues with specific phenotypes (3,19,20). In cancer progression, EMT appears to be at least partially responsible for the invasive nature of tumor cells and it facilitates metastasis by converting a non-motile cancerous epithelial cell into a motile mesenchymal cell capable of disseminating from the tumor mass and entering the circulatory or lymphatic system (21). In a number of studies, EMT has been associated with the progression of numerous types of cancer (22-24), but few of these studies concerned OS. The loss of E-cadherin is the hallmark of EMT in cancer development (25,26). The present study showed that with decreased E-cadherin expression levels, the malignant biology behavior of cells was repressed, indicating that EMT was also associated with the progress of OS (Figs. 2-4).

Snail is the first identified and most important transcriptional repressor of E-cadherin (27,28). It functions as a suppressor of the transcription of shotgun (an E-cadherin homolog) to control embryogenesis in *Drosophila* (3,29). Snail also plays a fundamental role in EMT by suppressing E-cadherin expression in mammalian cells (30,31). Overexpression of Snail has been identified in epithelial and endothelial cells of invasive breast

cancer but the overexpression of Snail is not detected in normal breast cells. The expression of Snail in breast carcinomas is associated with metastasis, tumor recurrence and poor prognosis (32-34). In a previous study, it was shown that Snail-1 was overexpressed in SaOS₂ cells (5). Snail also downregulates the expression levels of other epithelial molecules, including claudins, occludins and Mucl, and induces the expression of genes associated with a mesenchymal and invasive phenotype, such as fibronectin and matrix metalloproteinase-9. The Snail family of zinc-finger transcription factors consists of Snail-1 (Snail), Snail-2 (Slug) and Snail-3 (Smuc) (3). In the present study Snail-1 was focused on and it was hypothesized that Snail-1 is able to regulate EMT in OS through E-cadherin.

To test this hypothesis, SaOS₂ cells were treated with shRNA-Snail-1. As a result, following inhibition of Snail-1, the expression levels of E-cadherin decreased and the cells were less able to grow and invade and easily underwent apoptosis. E-cadherin is involved in EMT associated with carcinogenesis (25,27,28). Loss of E-cadherin has been causally associated with the transition of adenoma to carcinoma and the acquisition of migration capacity. Therefore, according data in the present study (Fig. 1), we considered that inhibition of the expression of Snail-1 prevents EMT and induces E-cadherin expression in OS. The results of the present study predict that patients with OS with high levels of Snail-1 and low levels of E-cadherin have a poor prognosis for the progression of OS. The expression levels of Snail-1 and E-cadherin may be used as indicators of the progression of OS. The monitoring of tumor overexpression of Snail-1 and E-cadherin by reverse transcription-PCR analysis of the RNA present in the serum/plasma may be useful as a non-invasive method for selecting suitable patients for therapy.

In conclusion, the present study indicates that Snail-1 is a regulator of E-cadherin and inhibition of Snail-1 represses EMT in OS, therefore Snail-1 has potential as a target of OS therapy.

References

1. Ferguson WS and Goorin AM: Current treatment of osteosarcoma. *Cancer Invest* 19: 292-315, 2001.
2. Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. *Cancer* 115: 1531-1543, 2009.
3. Nieto MA: The snail superfamily of zinc-finger transcription factors. *Nat Rev Mol Cell Biol* 3: 155-166, 2002.
4. Ferrari S, Smeland S, Mercuri M, *et al*: Italian and Scandinavian Sarcoma Groups: Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. *J Clin Oncol* 23: 8845-8852, 2005.
5. Yang H, Zhang Y, Zhou Z, *et al*: Snail-1 regulates VDR signaling and inhibits 1,25(OH)-D₃ action in osteosarcoma. *Eur J Pharmacol* 670: 341-346, 2011.
6. Perez-Moreno M, Jamora C and Fuchs E: Sticky business: orchestrating cellular signals at adherens junctions. *Cell* 112: 535-548, 2003.
7. Takeichi, M: Morphogenetic roles of classic cadherins. *Curr Opin Cell Biol* 7: 619-627, 1995.
8. Huber O, Bierkamp C and Kemler R: Cadherins and catenins in development. *Curr Opin Cell Biol* 8: 685-691, 1996.
9. De Wever O and Mareel M: Role of tissue stroma in cancer cell invasion. *J Pathol* 200: 429-447, 2003.
10. Vleminckx K, Vakaet L Jr, Mareel M, *et al*: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. *Cell* 66: 107-119, 1991.
11. Perl AK, Wilgenbus P, Dahl U, Semb H and Christofori G: A causal role for E-cadherin in the transition from adenoma to carcinoma. *Nature* 392: 190-193, 1998.
12. Batlle E, Sancho E, Franci C, *et al*: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. *Nat Cell Biol* 2: 84-89, 2000.
13. Kansara M and Thomas DM: Molecular pathogenesis of osteosarcoma. *DNA Cell Biol* 26: 1-18, 2007.
14. Tang N, Song WX, Luo J, *et al*: Osteosarcoma development and stem cell differentiation. *Clin Orthop Relat Res* 466: 2114-2130, 2008.
15. Meyers PA, Schwartz CL, Krailo MD, *et al*: Children's Oncology Group: Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. *J Clin Oncol* 26: 633-638, 2008.
16. Kager L, Zoubek A, Potschger U, *et al*: Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. *J Clin Oncol* 21: 2011-2018, 2003.
17. Klymkowsky MW and Savagner P: Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. *Am J Pathol* 174: 1588-1593, 2009.
18. Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D, *et al*: A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. *EMBO J* 24: 3446-3458, 2005.
19. Yang J, Mani SA, Donaher JL, *et al*: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell* 117: 927-939, 2004.
20. Tlsty TD and Coussens LM: Tumor stroma and regulation of cancer development. *Annu Rev Pathol* 1: 119-150, 2006.
21. Yehiely F, Moyano JV, Evans JR, *et al*: Deconstructing the molecular portrait of basal-like breast cancer. *Trends Mol Med* 12: 537-544, 2006.
22. Lacroix M, Toillon R and Leclercq G: Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. *Endocr Relat Cancer* 11: 497-522, 2004.
23. Zhuang Z, Lininger RA, Man YG, *et al*: Identical clonality of both components of mammary carcinosarcoma with differential loss of heterozygosity. *Mod Pathol* 10: 354-362, 1997.
24. Berx G, Cleton-Jansen AM, Strumane K, *et al*: E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. *Oncogene* 13: 1919-1925, 1996.
25. Castro Alves C, Rosivatz E, Schott C, *et al*: Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. *J Pathol* 211: 507-515, 2007.
26. Saegusa M, Hashimura M, Kuwata T and Okayasu I: Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. *Am J Pathol* 174: 2107-2115, 2009.
27. Moll R, Mitze M, Frixen UH and Birchmeier W: Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. *Am J Pathol* 143: 1731-1742, 1993.
28. Côme C, Magnino F, Bibeau F, *et al*: Snail and slug play distinct roles during breast carcinoma progression. *Clin Cancer Res* 12: 5395-5402, 2006.
29. Peinado H, Ballestar E, Esteller M and Cano A: Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. *Mol Cell Biol* 24: 306-319, 2004.
30. Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? *Nat Rev Cancer* 7: 415-428, 2007.
31. Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. *Nat Rev Mol Cell Biol* 7: 131-142, 2006.
32. Barrallo-Gimeno A and Nieto MA: The Snail genes as inducers of cell movement and survival: implications in development and cancer. *Development* 132: 3151-3161, 2005.
33. Martin TA, Goyal A, Watkins G and Jiang WG: Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. *Ann Surg Oncol* 12: 488-496, 2005.
34. Parker BS, Argani P, Cook BP, *et al*: Alterations in vascular gene expression in invasive breast carcinoma. *Cancer Res* 64: 7857-7866, 2004.